TNX-601 extended-release medicine for adults with depression
About this title
Read the official source — NCT05686408Researchers compared TNX-601 ER and placebo to find out how the approaches affected depression symptoms in people with depression.
Understand this study
What did researchers investigate?
Researchers compared TNX-601 ER and placebo to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 132
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05686408
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock · Bellflower · Glendale
24 more locations
- Lemon Grove
- Oceanside
- Orange
- Riverside
- San Diego
- Sherman Oaks
- Temecula
- Denver
- Cromwell
- Fort Myers
- Jacksonville
- Lauderhill
- Miami Lakes
- Orlando
- Atlanta
- Decatur
- Boise
- Chicago
- Berlin
- Portland
- Memphis
- Austin
- Dallas
- Everett
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared TNX-601 ER and placebo to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Tonix Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including TNX-601 ER and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
